Heron Therapeutics (HRTX) Accumulated Depreciation & Amortization (2016 - 2025)
Heron Therapeutics (HRTX) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $12.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 27.83% year-over-year to $12.9 million, compared with a TTM value of $12.9 million through Dec 2025, down 27.83%, and an annual FY2025 reading of $12.9 million, down 27.83% over the prior year.
- Accumulated Depreciation & Amortization was $12.9 million for Q4 2025 at Heron Therapeutics, down from $17.8 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $17.8 million in Q4 2024 and bottomed at $12.9 million in Q4 2025.
- Average Accumulated Depreciation & Amortization over 5 years is $15.1 million, with a median of $14.3 million recorded in 2022.
- The sharpest move saw Accumulated Depreciation & Amortization rose 21.81% in 2021, then dropped 27.83% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $13.2 million in 2021, then increased by 7.93% to $14.3 million in 2022, then rose by 19.14% to $17.0 million in 2023, then increased by 4.81% to $17.8 million in 2024, then decreased by 27.83% to $12.9 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for HRTX at $12.9 million in Q4 2025, $17.8 million in Q4 2024, and $17.0 million in Q4 2023.